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Abstract
Introduction: The specific uptake size index (SUSI) of striatal FP-CIT uptake is independent of spatial resolution in
the SPECT image, in contrast to the specific binding ratio (SBR). This suggests that the SUSI is particularly
appropriate for multi-site/multi-camera settings in which camera-specific effects increase inter-subject variability of
spatial resolution. However, the SUSI is sensitive to inter-subject variability of striatum size. Furthermore, it might be
more sensitive to errors of the estimate of non-displaceable FP-CIT binding. This study compared SUSI and SBR in
the multi-site/multi-camera (MULTI) setting of a prospective multi-center study and in a mono-site/mono-camera
(MONO) setting representative of clinical routine.
Methods: The MULTI setting included patients with Parkinson’s disease (PD, n = 438) and healthy controls (n = 207)
from the Parkinson Progression Marker Initiative. The MONO setting included 122 patients from routine clinical
patient care in whom FP-CIT SPECT had been performed with the same double-head SPECT system according to
the same acquisition and reconstruction protocol. Patients were categorized as “neurodegenerative” (n = 84) or
“non-neurodegenerative” (n = 38) based on follow-up data. FP-CIT SPECTs were stereotactically normalized to MNI
space. SUSI and SBR were computed for caudate, putamen, and whole striatum using unilateral ROIs predefined in
MNI space. SUSI analysis was repeated in native patient space in the MONO setting. The area (AUC) under the ROC
curve for identification of PD/“neurodegenerative” cases was used as performance measure.
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Results: In both settings, the highest AUC was achieved by the putamen (minimum over both hemispheres),
independent of the semi-quantitative method (SUSI or SBR). The putaminal SUSI provided slightly better
performance with ROI analysis in MNI space compared to patient space (AUC = 0.969 vs. 0.961, p = 0.129). The SUSI
(computed in MNI space) performed slightly better than the SBR in the MULTI setting (AUC = 0.993 vs. 0.991, p = 0.
207) and slightly worse in the MONO setting (AUC = 0.969 vs. AUC = 0.976, p = 0.259). There was a trend toward
larger AUC difference between SUSI and SBR in the MULTI setting compared to the MONO setting (p = 0.073).
Variability of voxel intensity in the reference region was larger in misclassified cases compared to correctly classified
cases for both SUSI and SBR (MULTI setting: p = 0.007 and p = 0.012, respectively).
Conclusions: The SUSI is particularly useful in MULTI settings. SPECT images should be stereotactically normalized
prior to SUSI analysis. The putaminal SUSI provides better diagnostic performance than the SUSI of the whole
striatum. Errors of the estimate of non-displaceable count density in the reference region can cause misclassification
by both SUSI and SBR, particularly in borderline cases. These cases might be identified by visual checking FP-CIT
uptake in the reference region for particularly high variability.
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Introduction
Single-photon emission computed tomography
(SPECT) with the I-123 labeled dopamine transporter
(DAT) ligand FP-CIT is widely used for detection (or
exclusion) of nigrostriatal degeneration in patients with
clinically uncertain parkinsonian syndrome (PS) [1].
Semi-quantitative analysis of striatal FP-CIT uptake has
the potential to support visual interpretation of the
SPECT images [2, 3].
Semi-quantitative analysis in radionuclide imaging
often aims at estimating the binding potential (BP), first
defined by Mintun and co-workers as BP = Bmax / KD,
where Bmax is the density of available binding sites
(here DAT) and 1/KD is the affinity of the tracer (here
FP-CIT) for the binding site [4]. The binding potential is
a measure of the capacity of the region of interest (ROI)
for specific binding of the tracer, that is, binding to the
binding site of interest. More generally, a binding poten-
tial can be defined as the equilibrium concentration of
specific binding to some other reference concentration
[5]. The most widely used binding potential is the
non-displaceable binding potential BPnd based on the
concentration of the non-displaceable (by blocking of
the binding site) tracer in the ROI as reference, i.e.,
BPnd ¼ Cs=Cnd; ð1Þ
where Cs and Cnd are the equilibrium concentration of
specifically bound and non-displaceable tracer in the
ROI, respectively. Determination of BPnd requires dy-
namic imaging and arterial blood sampling for full tracer
kinetic modeling. This is not feasible in clinical routine
so that a number of methods have been developed to es-
timate BPnd from a single static scan during equilibrium
(for FP-CIT approximately given between 3 and 6 h after
i.v. injection [6]). The most widely used among these
methods is the specific binding ratio (SBR) defined by
the formula [7]
SBR ¼ ðC−CRÞ=CR; ð2Þ
where C is the total count concentration in the striatal
ROI, and CR is the total count concentration in a refer-
ence region (almost) void of DAT. The SBR according to
formula (2) is based on the assumption that CR approxi-
mates the count concentration originating from non-dis-
placeable FP-CIT binding in the striatal ROI (the
difference C – CR then approximates the specific count
density originating from FP-CIT bound to DAT in the
striatal ROI). The striatal ROI for computation of the
SBR usually anatomically delineates the striatum or the
striatal subregion of interest such as caudate nucleus or
putamen [8, 9]. A major limitation of the SBR according
to formula (2) is the strong underestimation of the stri-
atal FP-CIT concentration C in the SPECT images due
to partial volume effects caused by limited spatial reso-
lution of SPECT. The recovery of actual striatal FP-CIT
concentration in SPECT images typically is only about
50% if no correction for partial volume and other de-
grading effects is performed [10–12]. In addition to
strong underestimation of the SBR, partial volume ef-
fects cause additional variability. This is due to the fact
that the magnitude of the partial volume effect strongly
depends on the size and shape of the striatum and the
spatial resolution in the reconstructed SPECT image.
Spatial resolution varies between SPECT cameras de-
pending on both, hardware and acquisition/reconstruc-
tion protocol. The additional variability of the SBR
associated with the use of different SPECT cameras
negatively impacts the utility of the SBR, particularly in
multi-site and in single-site/multi-camera settings or
when normal values and cut-offs obtained from healthy
subjects at one site are to be used at other sites [13, 14].
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Only in an ideal situation in which all main causes of in-
accuracy and imprecision of SPECT (attenuation, scatter,
partial volume effects, statistical noise) were properly
dealt with, the true SBR value would be obtained with
any SPECT camera and reduction of inter-camera vari-
ability would naturally follow from accuracy.
The specific uptake size index (SUSI) has been pro-
posed to improve accuracy of semi-quantitative analysis
in FP-CIT SPECT in practice [7, 15, 16]. It has been
thoroughly validated in phantom studies where true
count densities are known [15, 17]. The SUSI eliminates
partial volume effects by replacing count density in the
striatal ROI by a measure of total counts in the ROI.
More precisely, the SUSI is defined as
SUSI ¼ ðT−CR VÞ=CR; ð3Þ
where T is the total number of counts originating from a
large striatal ROI, V is the volume of the striatal ROI, and
CR is the count concentration in the reference region.
The striatal ROI for the computation of the SUSI is
chosen sufficiently large around the striatum to guarantee
that all counts originating from the striatum are detected
within this ROI. Assuming that image reconstruction is
“activity conserving” (that is, counts are neither lost nor
artificially produced by the reconstruction, although lim-
ited spatial resolution can cause counts originating from
the striatum to be localized outside of the striatum), sum-
ming the activity over all voxels within the large striatum
ROI collects all counts originating from the striatum. This
holds true independently of the spatial resolution in the
reconstructed SPECT image as long as the ROI is large
enough to encompass all counts originating from the stri-
atum. Thus, the SUSI is independent of spatial resolution
[15]. The SUSI approach can be seen as a method for par-
tial volume correction of the SBR. This is due to the fact
that SBR = SUSI / Vs, where Vs is the actual volume of the
striatum, as is easily derived from Eqs. (2) and (3) [15].
The SUSI has been used successfully for the quantita-
tive characterization of age effects on DAT availability in
healthy subjects from the European normal control data-
base of FP-CIT SPECT (ENC-DAT) [18]. A total of 13
sites using ten different SPECT camera models contrib-
uted to the ENC-DAT study.
The SUSI is typically computed in the original SPECT im-
ages in patient space after manual reorientation [7, 15, 16]. A
limitation of the SUSI computed in patient space is that it
also depends on the size of the striatum, not via partial vol-
ume effects as the SBR, but via the total amount of specific-
ally bound FP-CIT that increases with increasing size of the
striatum (assuming constant DAT concentration). Thus,
inter-subject variability of striatum size causes additional
variability of the SUSI that might limit its power to detect
nigrostriatal degeneration. The impact of inter-subject
variability of striatum size on the SUSI might be eliminated
by concentration-preserving stereotactical normalization of
the SPECT images into an anatomical standard space prior
to ROI analysis. Inter-subject variability of partial volume ef-
fects cannot be eliminated this way.
A recent study suggested the SUSI to be more sensitive
than the SBR to errors of the estimate of non-displaceable
count density in the striatum by the count density CR in the
reference region [19]. In both methods, SBR and SUSI, the
reference region is used to correct the striatal signal for
non-displaceable “background” in the striatum ROI that di-
lutes the effect of nigrostriatal degeneration in these mea-
sures if not corrected for. It is evident that the background
contribution increases when the ROI size increases beyond
the anatomical boundaries of the striatum. Thus, the relative
magnitude of the correction for non-displaceable back-
ground increases with increasing ROI size. As a conse-
quence, the computed measure of specific striatal binding
(SBR or SUSI) might be more sensitive to errors (including
statistical noise) of the estimate of non-displaceable FP-CIT
binding the larger the striatal ROI.
Aim of the present study was to compare the SUSI and
the SBR with respect to detection of nigrostriatal degener-
ation in (i) a sample of patients with PS in whom FP-CIT
SPECT has been performed with the same SPECT camera
using the same acquisition protocol with radius of rotation
within very tight limits [20] and the same reconstruction
protocol (mono-site/mono-camera (MONO) setting) and
(ii) in the multi-site/multi-camera (MULTI) setting of the
Parkinson Progression Markers Initiative (PPMI) [21].
Inter-subject variability of spatial resolution in the SPECT
images most likely was larger in the MULTI setting com-
pared to the MONO setting (due to camera-specific vari-
ability of spatial resolution in the MULTI setting). The
primary hypothesis put to test was that the diagnostic per-
formance of the SUSI relative to the SBR is better in the
MULTI setting compared to the MONO setting (due to
its stability with respect to varying spatial resolution in the
SPECT images), particularly when the SUSI is computed
after stereotactical normalization (in order to eliminate
inter-subject variability of striatum size) rather than in
raw images in patient space [7]. The secondary hypothesis
put to test was that the variability of the count density in
the reference region impacts the diagnostic performance
of both SUSI and SBR, and that the effect is larger for the
SUSI than for the SBR.
Materials and methods
Mono-site/mono-camera setting
One hundred twenty-two patients in whom FP-CIT
SPECT had been performed for detection (or exclusion)
of nigrostriatal degeneration as part of routine clinical
work-up were recruited retrospectively from the patient
database of the Department of Nuclear Medicine of the
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University Medical Center Freiburg. The patients were
categorized into two groups: “neurodegenerative PS” and
“non-neurodegenerative PS.” The neurodegenerative group
(n= 84, 39 females, 67.3 ± 10.0 years) comprised (i) the Lewy
body disease spectrum (n= 60) including Parkinson’s disease
(PD, n= 41), PD dementia (PDD, n= 5), and dementia with
Lewy bodies (DLB, n= 14), and (ii) atypical parkinsonian syn-
dromes (APS, n= 24) including multiple systems atrophy
(MSA-P and MSA-P/C, n= 7), progressive supranuclear
palsy (PSP, n= 13), and corticobasal degeneration (CBD, n=
4). The non-neurodegenerative group (n= 38, 15 females,
70.0 ± 8.0 years) comprised (i) essential tremor (n = 2), (ii)
vascular parkinsonism (VaP, n = 7), (iii) drug-induced
parkinsonism (n = 11), (iv) psychogenic parkinsonism
(n = 1), (v) possible Alzheimer’s disease (AD, n = 11),
and (vi) normal pressure hydrocephalus (NPH, n = 6).
The clinical diagnoses were established by a movement
disorder specialist based on current consensus criteria
and review of all relevant medical charts and clinical
follow-up data (mean follow-up 26.8 ± 14.5 months).
Patients with other than the listed diagnosis were
excluded.
FP-CIT SPECT had been performed according to com-
mon guidelines [22, 23]. The same double-head SPECT sys-
tem (Siemens E.CAM) and the same acquisition protocol
had been used in all patients (thyroid uptake blocked with
sodium perchlorate, 3 h uptake period after intravenous
bolus injection of 193 ± 8 MBq FP-CIT; low-energy
high-resolution parallel-hole collimators, 60 projections of 30
s duration with each head along a scan arc of 180° (i.e. 3°
angular sampling), radius of rotation = 13.5 ± 0.3 cm, en-
ergy window 144–168 keV, acquisition matrix 128 × 128,
zoom factor 1.23). In order to ensure consistent image re-
construction in all patients, projection data were exported
from the archive and retrospectively reconstructed by
three-dimensional ordered subset expectation
maximization (OSEM) with resolution recovery using the
Flash3D algorithm of the scanner software. The following
parameter settings were used as previously proposed for
FP-CIT SPECT specifically with the E.CAM camera to
provide a good compromise between delineation of striatal
substructures for visual inspection, recovery of striatal
tracer uptake, and noise of non-displaceable tracer uptake
in the reference region for semi-quantitative analysis [24]:
8 iterations, 8 subsets, postfiltering with a Gaussian kernel
with 8 mm full-width-at-half-maximum (FWHM). Uniform
post reconstruction attenuation correction was performed
according to Chang (first order, broad-beam attenuation
coefficient μ = 0.12/cm); no scatter correction was per-
formed. Voxel size was 3.9 × 3.9 × 3.9 mm3.
Multi-site/multi-camera setting
Data were obtained from the Parkinson’s Progression
Markers Initiative (PPMI) database (https://www.ppmi-
info.org/access-data-specimens/download-data/) [21].
Up-to-date information on the PPMI is available at www.
ppmi-info.org. The PPMI is a longitudinal, multi-center
study that aims to assess the progression of clinical features,
imaging, and biologic markers in patients with (idiopathic)
PD and healthy control (HC) subjects. All PD patients were
in an early stage of the disease (diagnosis of PD within the
last 2 years prior to screening). Details of the eligibility cri-
teria are given at http://www.ppmi-info.org/wp-content/up-
loads/2014/01/PPMI-AM7-Protocol.pdf.
All FP-CIT scans available from the PPMI database on
22nd November 2017 were downloaded in DICOM for-
mat, independent of subgroup and visit (n = 1710). The
analyses of the present study included the first FP-CIT
SPECT of all HC subjects and all PD patients, that is,
the analyses included also FP-CIT SPECT at an “un-
scheduled” visit if FP-CIT SPECT at the screening visit
was not available. Furthermore, the analyses included
not only “regular” HC subjects and “regular” PD patients
but also subjects who (i) declined participation in the
PPMI study after the screening visit but before inclusion
in the study (n = 20), or (ii) withdrew agreement after in-
clusion in the study (n = 78), or (iii) were excluded from
participation in the study due to a reason not related to
FP-CIT SPECT (n = 23). This resulted in 656 FP-CIT
scans. Visual inspection resulted in exclusion of 11 of
these scans: three HC scans were excluded because of
clearly reduced striatal FP-CIT uptake (PPMI-ID 3221,
3478, 4095); eight PD scans were excluded because of
clearly normal FP-CIT uptake in the striatum (3027,
3289, 3290, 3534, 3618, 3623, 3660, 3863). This resulted
in the inclusion of a total of 645 FP-CIT SPECTs: 438 of
PD patients and 207 of HC subjects.
FP-CIT SPECT data had been acquired at 24 different
centers using different SPECT camera models. All cen-
ters had been qualified for participation in the study by
an image center qualification process including a tech-
nical set up visit to optimize the acquisition and recon-
struction protocol for the specific SPECT system to be
used in the study [21]. The target dose of FP-CIT was
185 MBq (allowed range 110–185 MBq) and SPECT ac-
quisition was to be started 4 ± 0.5 h after i.v. administra-
tion of FP-CIT (PPMI imaging protocol at http://www.
ppmi-info.org/study-design/research-documents-and-
sops/). Raw projection data had been transferred to the
PPMI imaging core lab for central image reconstruction
using an OSEM algorithm on a HERMES workstation
(Hermes Medical Solutions, Stockholm, Sweden) [25].
PMOD (PMOD Technologies, Zurich, Switzerland) had
been used for attenuation correction. Ellipses were
drawn on the images and 0th order Chang attenuation
correction was applied using a site-specific μ empirically
derived from phantom data. Standard 3D Gaussian
post-smoothing (6.0 mm FWHM) was applied. Only
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preprocessed images that have been stereotactically nor-
malized into the anatomical space of the Montreal
Neurological Institute (MNI) were available for down-
load. The images were in DICOM format with 91 ×
109 × 91 cubic voxels of 2 mm edge length.
Semi-quantitative analyses
All semi-quantitative analyses were performed fully
automatically using a MATLAB script.
SBR was computed according to formula (2) with ROI
analysis in MNI space. For this purpose, individual
FP-CIT SPECTs were transformed (affine, that is, without
warping) into MNI space using the Statistical Parametric
Mapping software package (version SPM12) and a
custom-made FP-CIT template (Fig. 1). Unilateral ROIs
for caudate, putamen, and entire striatum (= union of
caudate and putamen ROI) predefined in MNI space by
the automatic anatomic labeling (AAL) atlas [26] available
in the PickAtlas of the Wake Forest University were used
(Fig. 1a) [27]. In addition, custom-made unilateral ROIs
for anterior and posterior putamen manually predefined
in MNI space were tested (Fig. 1b). Count concentration
within a ROI was characterized by the average intensity
over all voxels within the ROIs. The 75th percentile of the
count density in a reference region comprising the whole
brain without striata, thalamus, and brain stem was used
as estimate of non-displaceable count density (Fig. 1d)
[28].
The SUSI was computed according to formula (3) with
ROI analysis in MNI space. It was computed separately
for unilateral caudate and unilateral putamen using large
three-dimensional unilateral ROIs predefined in MNI
space (Fig. 1c). The union of large caudate and large pu-
tamen ROI was used to compute the SUSI of the entire
unilateral striatum. In the MONO setting, SUSI analysis
was repeated in native patient space. For this purpose, the
FP-CIT template was stereotactically normalized into patient
space (affine transformation). The resulting transformation
was used to map the ROIs from MNI space to the patient’s
FP-CIT SPECT.
Statistical analyses
SUSI and SBR were tested for identification of “neurode-
generative PS” in the MONO setting and for identification
of PD patients in the MULTI setting using the minimum
over both hemispheres for both semi-quantitative mea-
sures. The area (AUC) under the receiver operating charac-
teristic (ROC) curve was employed as performance
measure. Total accuracy, sensitivity, and specificity were
computed with the cut-off fixed by Youden’s criterion [29].
In order to test for potential impact of individual puta-
men size on the diagnostic performance of the puta-
minal SUSI computed in patient space, the volume of
the AAL putamen ROI after transformation into patient
space was used as measure of individual putamen size
(mean of both hemispheres). Putamen size was com-
pared between true positive, true negative, false positive,
and false negative cases as classified by the SUSI com-
puted in patient space. Univariate analysis of variance
was used for this purpose.
In order to test the secondary hypothesis, that is, the im-
pact of the uncertainty of the estimate of non-displaceable
count density by the 75th percentile of voxel intensities in
the reference region on the diagnostic performance of
SUSI and SBR, the interquartile range (IQR) of voxel in-
tensities in the reference region relative to the 75th per-
centile of voxel intensities in the reference region was
used as uncertainty measure (relative IQR). First, relative
IQR was compared between correctly classified scans (true
positive or true negative) and incorrectly classified scans
(false positive or false negative) using unpaired t tests. This
was done separately for SUSI and SBR. Second, SUSI and
Fig. 1 Anatomical caudate and putamen ROIs from the AAL atlas (a), custom-made anatomical ROIs of anterior and posterior putamen (b), large
ROIs of caudate and putamen (c), and reference region (d). All ROIs are three-dimensional. The ROIs are overlaid to the custom-made FP-CIT
template used as target for stereotactical normalization. The anatomical ROIs in (a) and (b) were used for computation of the SBR. The large ROIs
in (c) were used for computation of the SUSI. The custom-made FP-CIT template was obtained by averaging the stereotactically normalized
images of 94 visually normal FP-CIT SPECT scans
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SBR were compared with respect to the difference of the
relative IQR between correctly classified scans and incor-
rectly classified scans using univariate analysis of variance
of relative IQR with both, correctness of the SUSI-based
classification and correctness of the SBR-based classifica-
tion as fixed factors. Cut-offs fixed by Youden’s criterion
were used to categorize scans as correctly or incorrectly
classified.
In quantitative terms, the primary hypothesis of the
study (the diagnostic performance of the SUSI relative to
the SBR is better in the MULTI setting than in the
MONO setting) states that (AUCSUSI – AUCSBR)
(MULTI) > (AUCSUSI – AUCSBR) (MONO), where AUC-
SUSI is the AUC of the putaminal SUSI and AUCSBR is
the AUC of the putaminal SBR. Bootstrapping with
100,000-fold resampling was used to estimate the distri-
bution of (AUCSUSI – AUCSBR), separately for the
MULTI and the MONO setting. Then, the distribution
of (AUCSUSI – AUCSBR) was compared between the
MULTI and the MONO setting by generating 10,000
random pairs of (AUCSUSI – AUCSBR) (MULTI) and
(AUCSUSI – AUCSBR) (MONO) from their respective
distributions and counting the number of random pairs
that fulfilled the alternative hypothesis (AUCSUSI –
AUCSBR) (MULTI) ≤ (AUCSUSI – AUCSBR) (MONO).
Results
Fully automatic affine transformation of FP-CIT SPECT
from patient space into the anatomical MNI template
space or vice versa worked properly in all cases
according to visual inspection. Reliable spatial trans-
formation is required for automatic semi-quantitative
analysis with standard ROIs predefined in template
space.
Mono-site/mono-camera setting
SUSI and SBR showed better diagnostic performance
with the putamen as region of interest compared to
caudate and whole striatum (Table 1). The AUC pro-
vided by the putaminal measures was largest for the SBR
of the posterior putamen (AUC = 0.981) followed by SBR
of the whole putamen (AUC = 0.976). The putaminal
SUSI showed slightly worse performance, particularly
when computed in patient space (AUC = 0.961, DeLong
test p = 0.036 compared to SBR of the whole putamen;
Table 1, Fig. 2a). Stereotactical normalization prior to
ROI analysis improved the performance of the putaminal
SUSI from AUC = 0.961 to AUC = 0.969, but the differ-
ence did not reach statistical significance (p = 0.129,
Table 1). Classification of patients (as “neurodegenera-
tive PS” or “non-neurodegenerative PS”) was incorrect in
7 (5.7%), 12 (9.8%), and 8 (6.6%) of the 122 patients
when based on putaminal SBR, putaminal SUSI com-
puted in patient space, or putaminal SUSI computed in
MNI space, respectively (Table 1).
Classification based on putaminal SUSI computed in
patient space or putaminal SBR was discrepant in seven
patients (5.7%). All these discrepant cases had “neurode-
generative PS” and presented with borderline findings in
FP-CIT SPECT (Fig. 3). Classification based on
Table 1 Area (AUC) under the ROC curve, cut-off (based on Youden’s criterion), and resulting total accuracy, sensitivity, and
specificity for identification of neurodegenerative etiology of parkinsonism (mono-site/mono-camera setting) or PD (multi-site/multi-
camera setting). (Cau = caudate, Put = putamen, Str = striatum, ant = anterior, post = posterior)
SBR SUSI in MNI space SUSI in patient space





































Cut-off 1.829 2.383 1.866 1.776 2.051 16.418 16.974 34.902 12.913 8.371 23.653
Accuracy 0.672 0.943 0.885 0.943 0.877 0.705 0.934 0.877 0.770 0.902 0.877
Sensitivity 0.762 0.940 0.857 0.917 0.881 0.643 0.929 0.869 0.821 0.881 0.881





























Cut-off 1.781 2.068 1.776 1.597 1.960 21.229 14.799 39.171 – – –
Accuracy 0.780 0.953 0.898 0.980 0.930 0.839 0.964 0.933 – – –
Sensitivity 0.719 0.943 0.872 0.973 0.916 0.822 0.961 0.945 – – –
Specificity 0.908 0.976 0.952 0.995 0.961 0.874 0.971 0.908 – – –
Statistical testing was restricted to caudate versus caudate, putamen versus putamen, and striatum versus striatum
a/aa/aaaDeLong test p < 0.05/0.01/0.005 compared to SBR
b/bb/bbbDeLong test p < 0.05/0.01/0.005 compared to SUSI in MNI space
c/cc/cccDeLong test p < 0.05/0.01/0.005 compared to SUSI in patient space
Buchert et al. EJNMMI Research            (2019) 9:37 Page 6 of 13
putaminal SUSI computed in patient space was correct
(true positive) and SBR-based classification was incorrect
(false negative) in one of these patients. Classification
based on putaminal SUSI computed in patient space was
incorrect (false negative) and SBR-based classification
was correct (true positive) in the remaining six patients.
Putamen volume was smaller in the two false positive
cases compared to the 36 true negative cases based on pu-
taminal SUSI in patient space; it was larger in the ten false
negative cases compared to the 74 true positive cases
(Fig. 4). However, neither of the two differences reached
statistical significance according to analysis of variance with
standard of truth (“neurodegenerative PS” versus “non--
neurodegenerative PS,” p = 0.314) and correctness of pa-
tient space SUSI (true positive or true negative versus false
positive or false negative, p = 0.372) as fixed factors (stand-
ard of truth * correctness interaction p = 0.170).
The relative IQR of voxel intensities in the reference
region was not different between the 12 patients with in-
correct classification based on patient space SUSI
Fig. 2 ROC curves for identification of neurodegenerative etiology of parkinsonism (mono-site/mono-camera setting, a) or PD (multi-site/multi-
camera setting, b)
Fig. 3 FP-CIT SPECT images from the mono-site/mono-camera setting with discrepant classification as “neurodegenerative PS” or “non-
neurodegenerative PS” based on the putaminal SUSI computed in patient space versus classification based on the putaminal SBR. The upper row
shows transversal slices through the striatum in patient space. The lower row shows the same transversal slice with the transformed mask of
caudate, putamen and the reference region overlaid. dSUSI = 100*(individual SUSI – SUSI cutoff) / SUSI cutoff, dSBR = 100*(individual SBR – SBR
cutoff) / SBR cutoff
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compared to the remaining 110 patients (0.164 ± 0.012
versus 0.173 ± 0.024, t test p = 0.199).
Harmonized multi-site/multi-camera setting
In the multi-site/multi-camera setting, the SUSI was com-
puted in MNI space only, because the PPMI provides only
preprocessed FP-CIT SPECT images in MNI space, the
original FP-CIT images in patient space are not available.
Thus, all SUSI results in the multi-site/multi-camera set-
ting refer to the SUSI computed in MNI space.
In the harmonized MULTI setting, too, the putamen
achieved the highest performance with both SUSI and
SBR (Table 1). The AUC of the SUSI increased to AUC=
0.993 when the putamen was used as region of interest
from AUC= 0.978 for the whole striatum (p < 0.001).
The AUC provided by the putaminal measure was lar-
gest for the SBR of the posterior putamen (AUC =
0.998), followed by the SUSI (AUC = 0.993) and the SBR
of the whole putamen (AUC = 0.991) (Fig. 2b). The AUC
difference between SUSI and SBR of the whole putamen
did not reach statistical significance (p = 0.207). Classifi-
cation of subjects (as PD or HC) was incorrect in 30
(4.7%) and 23 (3.6%) of the 645 subjects when based on
putaminal SBR or putaminal SUSI, respectively (Table 1).
The relative IQR of voxel intensities in the reference
region was higher in the 23 subjects with incorrect
SUSI-based classification compared to the remaining 622
subjects with correct SUSI-based classification (0.15713 ±
0.03098 versus 0.14390 ± 0.02259, t test p= 0.007). The same
was true for the 30 subjects with incorrect SBR-based classi-
fication compared to the remaining 615 subjects (0.15474 ±
0.02612 versus 0.14387 ± 0.02278, t test p= 0.012).
Classification based on putaminal SUSI or on puta-
minal SBR was discrepant in 23 of the 645 patients
(3.6%). The relative IQR of voxel intensities in the refer-
ence region was higher in the 23 subjects with discrepant
classification compared to the remaining 622 subjects with
concordant classification (0.154 ± 0.028 versus 0.144 ±
0.023, t test p = 0.044). SUSI-based classification was cor-
rect and SBR-based classification was incorrect in two HC
subjects and 13 PD patients. SUSI-based classification was
incorrect and SBR-based classification was correct in three
HC subjects and 5 PD patients. The difference of relative
IQR between incorrectly classified scans and correctly
classified scans based on the SUSI was larger for scans
with correct SBR-based classification (0.157 ± 0.037, n = 8,
versus 0.144 ± 0.023, n = 607) compared to scans with in-
correct SBR-based classification (0.157 ± 0.029, n = 15, ver-
sus 0.152 ± 0.024, n = 15) (Fig. 5). However, the difference
was not significant according to univariate analysis of vari-
ance of relative IQR with correctness of the SUSI-based
classification and the correctness of the SBR-based classi-
fication as fixed factors (SUSI correctness * SBR correct-
ness interaction p = 0.482).
Fig. 4 Comparison of individual putamen volume between true positive and false negative cases and between true negative and false positive
cases as classified by the SUSI computed in patient space. None of the differences reached statistical significance
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SUSI versus SBR in harmonized multi-site versus mono-
camera setting
The putaminal SUSI performed slightly worse than the
putaminal SBR in the MONO setting (AUC = 0.969 ver-
sus 0.976, p = 0.259) and slightly better in the MULTI
setting (AUC = 0.993 versus 0.991, p = 0.207).
The distribution of the difference (AUCSUSI − AUCSBR)
in the MULTI setting and in the MONO setting esti-
mated by bootstrapping is shown in Fig. 6. Mean (AUC-
SUSI − AUCSBR) was 0.002 (95% CI -0.001–0.005) in the
MULTI setting and -0.007 (-0.021–0.004) in the MONO
setting. The sign test revealed a trend toward larger
(AUCSUSI – AUCSBR) in the MULTI setting compared to
the MONO setting (p = 0.073).
Discussion
SUSI and SBR showed better classification performance
with the putamen as region of interest compared to the
whole striatum. The difference was highly significant for
both SUSI and SBR (e.g., multi-site/multi-camera setting:
putaminal SUSI = 0.993, striatal SUSI = 0.978, p < 0.001,
Table 1). The fraction of misclassified cases was almost
twice as large for the SUSI of the whole striatum com-
pared to the putaminal SUSI (6.7% versus 3.6% in the
MULTI setting, Table 1). Thus, the SUSI should be used
with the putamen as striatal region of interest. This might
appear in conflict with the rationale of the SUSI at first
sight, because there is some loss of putaminal counts and
some contamination by counts from the caudate at the
boundary between putamen and caudate ROI. This prob-
ably explains that all previous studies used the SUSI with
the whole striatum as region of interest [7, 15, 16, 18, 19].
Furthermore, the putaminal SUSI depends on the defin-
ition of the putamen ROI, in contrast to the striatal SUSI
that is rather independent of the striatum ROI as long as
it is large enough [15]. However, the SBR has the same
limitations: the SBR of the (whole) putamen depends on
the putamen ROI, and it is affected by spill-out and
spill-in at the boundary between putamen and caudate
ROI. These limitations, therefore, should not prevent use
of the putaminal SUSI, considering the relevant improve-
ment in diagnostic accuracy it provides compared to the
conventional SUSI of the whole striatum. The large puta-
men ROI used for SUSI analysis in the present study ex-
cluded part of the anterior putamen in order to reduce
contamination of the putaminal SUSI by counts from the
caudate (Fig. 1c). As a result, the contribution of the pos-
terior putamen was pronounced in the putaminal SUSI.
This probably contributed to the excellent performance of
the putaminal SUSI in the multi-site/multi-camera setting.
In the MONO setting, putaminal SUSI computed in
patient space performed slightly worse than the SUSI
computed in MNI space (AUC = 0.961 versus 0.969, p =
0.129, total accuracy = 90.2% versus 93.4%, Table 1).
Fig. 5 Interquartile range (IQR) relative to the 75th percentile of the voxel intensity in the reference region according to correctness of SUSI-
based and SBR-based classification of the PPMI FP-CIT images as PD or HC (“correct” = true positive or true negative, “incorrect” = false positive or
false negative). The relative IQR is as measure of the uncertainty of the estimate of the non-displaceable count density by the 75th percentile of
the voxel intensity in the reference region
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Putamen volume was smaller in the two false positive
cases compared to the 36 true negative cases based on
putaminal SUSI in patient space; it was larger in the ten
false negative cases compared to the 74 true positive
cases (Fig. 4). This is in line with the fact that the puta-
minal SUSI increases with increasing putamen size so
that the SUSI tends to overestimate putaminal DAT con-
centration in patients with large putamen and to under-
estimate putaminal DAT density in patients with small
putamen. This can be avoided by scaling the putaminal
SUSI to individual putamen size estimated from individ-
ual high resolution MRI which, however, is not always
available in clinical routine. Alternatively, inter-subject
variability of putamen size can be reduced by
concentration-preserving stereotactical normalization,
that is, stereotactical normalization without modulation
to account for the amount of local expansion/contrac-
tion that typically is used in MRI-based morphometry to
guarantee that regional brain volume is the same in ana-
tomical standard space as in the original image in pa-
tient space. Based on the findings of this study, we
recommend stereotactical normalization prior to SUSI
analysis, although the effects of inter-subject variability
of putamen size on diagnostic performance of the SUSI
computed in patient space did not reach the level of
statistical significance (possibly due to the rather small
number of incorrectly classified cases).
Concerning the primary hypothesis put to test in this
study (the classification performance of the SUSI relative
to the SBR is better in the MULTI setting than in the
MONO setting), the putaminal SUSI (computed in MNI
space) performed slightly worse than the putaminal SBR
in the MONO setting (AUC = 0.969 versus 0.976) and
slightly better in the MULTI setting (AUC = 0.993 versus
0.991). This is in line with the primary hypothesis, al-
though neither the difference in the MONO setting nor
Fig. 6 Distribution of the performance difference AUCdiff = (AUCSUSI – AUCSBR) between putaminal SUSI and putaminal SBR in the mono-site/
mono-camera (MONO) setting and in the multi-site/multi-camera (MULTI) setting (a), and distribution of the double difference AUCdiffdiff = AUCdiff
(MULTI) – AUCdiff (MONO) (b). All distributions were estimated by bootstrapping with 100,000-fold resampling
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the difference in the MULTI setting reached statistical
significance (p = 0.259 and 0.207, respectively). However,
direct statistical comparison of the AUC difference be-
tween the SUSI and the SBR between the MULTI setting
and the MONO setting showed a trend toward larger
AUC difference in the MULTI setting compared to the
MONO setting (p = 0.073, Fig. 6), supporting the pri-
mary hypothesis. Thus, we recommend the use of the
SUSI in multi-site settings and in mono-site settings
with more than one SPECT camera.
The fact that the SUSI did not outperform the SBR
more clearly in the MULTI setting might be explained
by two factors. First, very successful harmonization of
SPECT image quality (including spatial resolution) in
the PPMI by careful adaption of the acquisition protocol
for each single camera and central image reconstruction
at a core imaging center. Second, the relative IQR of the
voxel intensity in the reference region was significantly
larger in cases that were incorrectly classified by the pu-
taminal SUSI compared to those that were correctly
classified. The same was observed for the putaminal
SBR. This demonstrates that the diagnostic performance
of both, SUSI and SBR, is affected by uncertainty of the
estimate of non-displaceable striatal FP-CIT count dens-
ity by the count density in the reference region. The dif-
ference of the relative IQR between cases that were
incorrectly classified by the putaminal SUSI and those
that were correctly classified by the putaminal SUSI was
larger in cases correctly classified by the putamen SBR
compared to those incorrectly classified by the putamen
SBR (Fig. 5). This is in line with the hypothesis that the
impact of uncertainty in the estimate of non-displaceable
count density is larger for the SUSI than for the SBR.
However, the difference did not reach statistical signifi-
cance. The small number of incorrectly classified cases
might have contributed to the lack of significance.
Goethals and co-workers compared the SUSI com-
puted in patient space and SBR computed in template
space for detection of nigrostriatal degeneration in a
mono-camera setting very similar to the mono-camera
setting in the present study [16]. The AUC under the
ROC curve for identification of neurodegenerative PS
was highest for the SUSI of the whole striatum (mini-
mum over left and right hemisphere, AUC = 0.859, 95%
CI 0.766–0.952). The highest AUC achieved among sev-
eral variants of the SBR was for the minimum over bilat-
eral caudate and bilateral putamen SBR (AUC = 0.830,
95% CI 0.727–0.932). The minimum of putaminal SBR
over both hemispheres was not considered in this study.
The different ranking of SUSI and SBR in the study by
Goethals and co-workers (striatal SUSI better than sub-
regional SBR) compared to the present study (putaminal
SBR better than striatal SUSI) most likely is due to meth-
odological differences in the computation of the SBR.
The following limitations of the present study should be
noted. First, the classification performance of SUSI and SBR
in FP-CIT SPECT not only depends on the setting (mul-
ti-site/multi-camera versus mono-site/mono-camera). Classi-
fication performance of both semi-quantitative measures also
depends on the subjects referred to FP-CIT SPECT.
The PPMI PD sample differs from the group of
patients with neurodegenerative PS in the clinical
mono-site/mono-camera sample in several respects,
particularly by inclusion of patients with atypical neuro-
degenerative PS (MSA, PSP, CBD) in the clinical
mono-site/mono-camera sample and the exclusion of
subjects without evidence of dopaminergic deficit
(SWEDD) from the PPMI PD sample [25]. There is also
a relevant difference between the PPMI group of healthy
control subjects and the non-neurodegenerative sub-
group of the clinical mono-site/mono-camera sample:
the latter included etiologies (e.g., vascular parkinson-
ism) that are associated with variable reduction of
striatal DAT availability in a considerable fraction of pa-
tients. The differences between the PPMI multi-site/
multi-camera research sample and the clinical mono-
site/mono-camera sample most likely explain the fact
that all tested semi-quantitative measures performed
better in the PPMI sample than in the clinical sample
despite the additional variability due to camera-specific
effects in the PPMI sample.
Second, the excellent performance of both SUSI and
SBR in the PPMI sample limits the power to detect per-
formance differences (ceiling effect). Good diagnostic
performance of FP-CIT SPECT independent of the ana-
lysis method in general makes it difficult to demonstrate
differences in the diagnostic performance between
methods and to reliably identify factors that might affect
performance [2].
Third, classification performance of semi-quantitative
measures also depends on the SPECT cameras, the acqui-
sition protocol (including radius of rotation and delay of
acquisition after tracer administration), the reconstruction
algorithm, and, in the multi-site/multi-camera setting, the
extent of harmonization of acquisition protocol and re-
construction algorithm. These factors not only affect the
absolute classification performance of both SUSI and SBR,
they also might affect the performance difference between
SUSI and SBR. This may affect the generalizability of the
results of the present study. In particular, it is to be ex-
pected that the SUSI more clearly outperforms the SBR in
multi-site/multi-camera settings with lower degree of
harmonization than in the PPMI.
Conclusion
The specific uptake size index (SUSI) of striatal FP-CIT
uptake is particularly appropriate for semi-quantitative
analysis in multi-site/multi-camera settings in which
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camera-specific effects increase inter-subject variability
of spatial resolution. SPECT images should be stereotac-
tically normalized prior to SUSI analysis in order to re-
duce the impact of inter-subject variability of striatum
size. The SUSI of the putamen provides better diagnostic
performance than the SUSI of the whole striatum. In
mono-camera settings without camera-specific inter-
subject variability of spatial resolution, the specific bind-
ing ratio (SBR) provides similar performance as the
SUSI. Errors of the estimate of non-displaceable count
density can cause misclassification by both, SUSI and
SBR, particularly in borderline cases. We recommend to
check for high uncertainty associated with high variabil-
ity of voxel intensity in the reference ROI in addition to
verification of proper placement of the ROI.
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